The focus will initially be on creating computational and digital pathology products, as well as AI-assisted algorithms.

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

Danaher (NYSE:DHR) recently announced a collaboration with AstraZeneca to develop innovative diagnostic tools, possibly adding momentum to its 1.59% share price increase over the past week. However, ...

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered di ...

Danaher and AstraZeneca have formed a partnership to develop diagnostic tools that help clinicians better determine which patients would benefit from precision medicine treatments. The venture ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing ...

jittawit.21/iStock via Getty Images Danaher (NYSE:DHR) has inked an agreement with AstraZeneca (NASDAQ:AZN) to develop diagnostic tests and tools that will help doctors determine which precision ...

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments. Based in ...

Danaher and AstraZeneca have formed a partnership to develop diagnostic tools that help clinicians better determine which patients would benefit from precision medicine treatments.